Triastek
Manufacturing · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
No. 24 Building Max Science Business Par...Phone Number
+86 2552713121Website
www.triastek.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Triastek
Triastek is an international pharmaceutical company founded in July 2015 by Dr. Senping Cheng, who has entrepreneurial experience both in China and the United States, and Dr. Xiaoling Li, an American pharmaceutical scientist and educator. It is committed to building a novel 3D printing pharmaceutical technology platform for dosage form design, product development, and intelligent manufacturing. In-house product development and co-development with partners are two main business models; in terms of co-development, Triastek has reached a number of agreements with top multinational and Chinese pharmaceutical companies. Triastek's mission is to be a global leader in the field of 3D printing pharmaceuticals and establish a new era of intelligent pharmaceutical manufacturing.Explore more
Triastek Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Triastek your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Triastek recently announced quarterly report
Check out if Triastek is spiking on competitors!
Check if Triastek has recently received funding, and reach out quickly before it becomes old news!
Triastek, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Triastek had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Triastek launches new products
Congratulate Masked Content for being promoted to Masked Content at Triastek
Funding: Get notified immidiatlly once Triastek has new funding data
Recommended Actions
Reach out to Masked Content who joined Triastek as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Triastek is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Triastek is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Triastek.
Triastek financials insights
Gather financial insights about Triastek, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$15M
2021
Series B
$50M
2023
Other Financing Round
$20.4M
Triastek Tech Stack
A closer look at the technologies used by Triastek
See more technologies
Most Recent Scoops
Partnership
Project
Partnership, Collaboration/Web Apps, Intellectual Property, Clinical Operations, Healthcare Technology
Funding
Partnership
Automation, Digital Technology
Funding
Triastek News & Media
Triastek D23 (Budesonide Ileum Targeted Tablets) Receives Positive Clinical Results
NANJING, China--(BUSINESS WIRE)-- #3DPrintingPharmaceutical--Triastek announces that its 3D printed drug product D23 (Budesonide Ileum Targeted Tablets for the treatment of IgAN) has achieved positive results in recent clinical study. D23 is budesonide delayed-release tablet made by 3D printing using Melt Extrusion Deposition (MED®) process first developed in scale by Triastek based on its proprietary 3D Microstructure for Intestine Targeting (3DμS®-IT) platform. This proprietary platform allowsTriastek Announces Research Collaboration and Platform Technology License Agreement with BioNTech to Advance 3D Printed Oral RNA Therapeutics
NANJING, China--(BUSINESS WIRE)-- #3DPrintingPharmaceuticals--Triastek Inc. ("Triastek"), a global leader in 3D printing pharmaceuticals, today announced that it has entered into a research collaboration and platform technology license agreement with BioNTech SE ("BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Under the agreement, the companies will develop RNA therapeutics for oral delivery based on 3D printing technology. TTriastek's 3D Printed Gastric Retention Product T22 Receives FDA Clearance of IND Application
NANJING, CHINA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- On January 27, Triastek announced that the U.S. Food and Drug Administration (FDA) granted clearance to proceed for the Investigational New Drug (IND) of the company's 3D-printed product T22, making it the first 3D printed gastric retention product to receive this designation. Triastek is preparing to initiate clinical studies with T22 to fast-track product development.Triastek Closes USD 20.4M Pre-C Funding Round
Triastek, a Nanjing, China-based company which specializes in 3D printing for pharmaceutical industry, raised USD 20.4M in Pre-C funding. The round was led by Guoxin Investment, with participation from Goldmine Multi-Family Office and existing investor Mr. Xiaodong Zheng, president of Shanghai Tofflon Science and Technology Co. Prior to this, Triastek was backed by Tasly Holding […] The post Triastek Closes USD 20.4M Pre-C Funding Round appeared first on FinSMEs.
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Triastek
Sign Up For FreeTo access detailed company insights
Triastek is an international pharmaceutical company founded in July 2015 by Dr. Senping Cheng, who has entrepreneurial experience both in China and the United States, and Dr. Xiaoling Li, an American pharmaceutical scientist and educator. It is committed to building a novel 3D printing pharmaceutical technology platform for dosage form design, prod... Read More
